European Pharmaceutical Review
FEBRUARY 27, 2024
The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.
European Pharmaceutical Review
JANUARY 10, 2023
The report offers predictive analysis of drugs entering the market or launching key indications in 2023. Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. Drug development in 2023 and beyond.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 2, 2022
. “ADHD has a significant impact on children and their families in Asia, and caregivers and healthcare providers are looking for innovative non-drug treatment options,” said Takeki Uehara, head of drug development and regulatory science at Shionogi. Image by Gemma Moll from Pixabay .
Express Pharma
SEPTEMBER 24, 2023
CYB-003, a small-molecule drug that is indicated for major depressive disorder, is expected to launch in the US in December 2027 and is forecast to generate $1.4 SPL-026 is also a small-molecule drug. It is expected to launch in the US in 2027 and in the EU in 2028 and generate $0.9 billion in sales in 2029.
FDA Law Blog: Biosimilars
AUGUST 23, 2023
FDA has made good progress on these initial goals, providing updates on the first four on the Digital Health Technologies (DHTs) for Drug Development website. Earlier this year, FDA published the Framework for the Use of Digital Health Technologies in Drug and Biological Product Development (DHT Framework).
Syner-G
JULY 7, 2023
Cell and gene therapies have been subjects of research for some time, but they have gained traction in real-world medicine and are projected to reach a market value of more than $36 billion by 2027. Drug development companies must embrace new technology. Efficient clinical and commercial manufacturing presents issues, too.
STAT
SEPTEMBER 12, 2024
Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate.
Expert insights. Personalized for you.
105 
Let's personalize your content